Etanercept

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for launch Basel, April 14, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the filing of an antitrust lawsuit in the US against Amgen, Inc. (Amgen), for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel® (etanercept), first approved by the US Food and Drug Administration (FDA) in 1998. Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi®+ (etanercept-szzs), by unlawfully purchasing and using certain patent rights to entrench its position in the market. In 2024, Enbrel® generated USD 3.3 billion in revenue in the US[1]. Sandoz received US FDA approval for Erelzi® in 2016. Today, Amgen is continuing to block entry of this important treatment option for approximately 7.5 million Americans living with chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis[2-6], many of whom could benefit from the cost savings and expanded access resulting from the introduction of high-quality, more-affordable biosimilar options. Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow Sandoz to launch Erelzi® as soon as possible. The company is also seeking damages, which could be tripled under applicable laws. The lawsuit was filed in the US District Court for the Eastern District of Virginia. *Enbrel® is a registered trademark of Amgen, Inc.+Erelzi® is a registered trademark of Sandoz Inc. About Erelzi® (etanercept-szzs)Erelzi® is the Sandoz biosimilar of the reference medicine Enbrel®. Erelzi® has been studied in a global development program, which included a comprehensive comparison of Erelzi® and Enbrel® at the analytical, preclinical, and clinical levels. The program included preclinical studies, pharmacokinetic (PK) studies, and the Phase III confirmatory safety and efficacy EGALITY study. Erelzi® is approved by the US FDA for the following indications: adult rheumatoid arthritis (RA), ankylosing spondylitis (AS), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and moderate to severe plaque psoriasis (PsO). IMPORTANT SAFETY INFORMATIONPlease see full Prescribing Information for Erelzi® here. DISCLAIMERThis Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. REFERENCES 1. Statista. Revenue of Amgen’s Enbrel by Region from 2011-2014. Available at: Revenue Enbrel worldwide by region 2024 | Statista [Last accessed: March 2025]2. Xu Y, Wu Q. Prevalence Trend and Disparities in Rheumatoid Arthritis among US Adults, 2005-2018. J Clin Med. 2021;10(15):3289. Available at: https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC8348893/ [Last accessed: March 2025]3. Johns Hopkins Arthritis Center. Ankylosing Spondylitis. Available at: https://www.hopkinsarthritis.org/arthritis-info/ankylosing-spondylitis/ [Last accessed: March 2025]4. About Juvenile Idiopathic Arthritis. Available at: https://www.arthritis.org/getmedia/6398ed64-029b-4629-82e7-bf91fa61d8f5/Juvenile-Idiopathic-Arthritis-JIA-FactSheet-101122.pdf [Last accessed: March 2025]5. National Psoriasis Foundation. Psoriasis Statistics. Available at: https://www.psoriasis.org/psoriasis-statistics [Last accessed: March 2025]6. Weiss PF. Polyarticular juvenile idiopathic arthritis: Clinical manifestations, diagnosis, and complications. Available at: https://www-uptodate-com.libproxy1.nus.edu.sg/contents/polyarticular-juvenile-idiopathic-arthritis-clinical-manifestations-diagnosis-and-complications [Last accessed: March 2025] CONTACTS Global Media Relations contactsInvestor Relations contactsGlobal.MediaRelations@sandoz.comInvestor.Relations@sandoz.comAlex Kalomparis+41 792 790285Craig Marks+44 781 8 94 2383Joerg E. Allgaeuer+49 171 838 4838Rupreet Sandhu+41 791 05472US Media Relations contacts Media.Info@sandoz.com Vicki Crafton+1 201 213 6338 Attachment Media release_Etanercept Amgen Antitrust Litigation_corrected

Amgen has enjoyed a monopoly on its blockbuster inflammatory disease drug Enbrel for almost 27 years now. After accumulating $86 billion in global sales, the company is still trying to keep biosimilars off the market, Sandoz alleged in a new lawsuit against Amgen. Sandoz’s lawsuit in Virginia district court seeks to immediately launch its biosimilar, Erelzi — which the FDA approved in 2016 — and alleges that Amgen will otherwise use a fortress of patents to keep biosimilars at bay until 2029. Sandoz claims Amgen since 2020 has unlawfully engaged in “cross-market bundling,” which allegedly involves ensuring a certain level of Enbrel rebates in exchange for giving Amgen drugs preferred placement on insurers’ and PBMs’ lists of covered drugs. Amgen declined to comment on pending litigation. Acquiring certain patents from Roche relating to TNFR fusion proteins, including Enbrel, “allowed Amgen to illegally prolong its U.S. Enbrel monopoly for at least an additional decade,” Sandoz alleges in the suit filed Friday. “While Amgen has been able to unlawfully hold back biosimilar competitors, like Sandoz, in the U.S. market, Sandoz launched its etanercept biosimilar in Europe more than eight years ago.” Enbrel, which pulled in more than $3 billion last year for Amgen, has seen steady price increases over the years and is approved to treat a range of disabling inflammatory diseases like rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Novartis, which was the parent company of Sandoz before being spun off in 2023, previously lost its attempt to have the US Supreme Court review the issue in a separate case. Sandoz claims in the latest suit that it would have earned about $1 billion from its biosimilar Erelzi over the last four years, if it had been able to launch. At the state level, Colorado has already sought to cap the price of Enbrel, which Amgen called “unconstitutional” in its suit over the price intervention last June.